ClinicalTrials.gg
CompletedNCT00939562Updated Dec 23, 2009Results posted

Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate

A Phase 4 interventional study of doxycycline monohydrate tablet and doxycycline carragenate tablet in Bacterial Infection, sponsored by Pfizer. Completed at 1 site in India. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-12-23.

Sponsored by Pfizer · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Bacterial Infections by Pfizer — none open to participants now, none under way, none of them phase 3. Bacterial Infections · Pfizer.

Enrollment
17th of 21
24 · median 134
Started
2008
with 3 others
Phase 4
5 of 28
none open now
Registered
21st of 28
by date

Among the 28 studies in Bacterial Infections by Pfizer, this one is the 17th largest by enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2008, is one of 5 in phase 4, and was the 21st registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

None of the 28 studies in Bacterial Infections by Pfizer is open now. The open studies under Bacterial Infections, anywhere →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies in Bacterial Infections by Pfizer as a file.
02

Study summary

The purpose of this protocol is to study if two different tablet formulations of doxycycline are bioequivalent to each other.

03

Conditions studied

  • Bacterial Infection

Browse trials for

Keywords

  • Bioequivalence
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects between the ages of 18 and 55 years.
  • (BMI) of 18 to 30 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of abnormality.
  • Any condition possibly affecting drug absorption.
  • A positive urine drug screen.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    doxycycline monohydrate tablet

    Drug: doxycycline monohydrate tablet

  • Active comparator
    doxycycline carragenate tablet

    Drug: doxycycline carragenate tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of Doxycycline

    Time frame: 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose.

  2. Area Under Plasma Concentration-Time Profile From Time Zero to Infinity (AUCinf) of Doxycycline

    AUCinf = Area under the plasma concentration-time profile from time zero (pre-dose) to infinity.

    Time frame: 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose.

07

Results

Posted Dec 23, 2009

Participant flow

Period 1
Participant flow — Period 1
MilestoneDoxycycline Monohydrate, Then Doxycycline CarragenateDoxycycline Carragenate, Then Doxycycline Monohydrate
Started1212
Completed1212
Not completed00
Period 2
Participant flow — Period 2
MilestoneDoxycycline Monohydrate, Then Doxycycline CarragenateDoxycycline Carragenate, Then Doxycycline Monohydrate
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) of Doxycycline
Time frame:
0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose.
Reported as:
Mean · ug/mL
Maximum Plasma Concentration (Cmax) of Doxycycline
ug/mLDoxycycline MonohydrateDoxycycline Carragenate
Maximum Plasma Concentration (Cmax) of Doxycycline2.526 ± 0.50902.442 ± 0.4585
Statistical analysis
  • Doxycycline Monohydrate vs Doxycycline Carragenate · Ratio: 102.95 · 90% CI 94.74 to 111.86The adjusted mean differences and 90% confidence intervals (CIs) were exponentiated to provide the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios. Doxycycline carragenate=Reference, doxycycline monohydrate=Test.
PrimaryArea Under Plasma Concentration-Time Profile From Time Zero to Infinity (AUCinf) of Doxycycline

AUCinf = Area under the plasma concentration-time profile from time zero (pre-dose) to infinity.

Time frame:
0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose.
Reported as:
Mean · ug*hr/mL
Area Under Plasma Concentration-Time Profile From Time Zero to Infinity (AUCinf) of Doxycycline
ug*hr/mLDoxycycline MonohydrateDoxycycline Carragenate
Area Under Plasma Concentration-Time Profile From Time Zero to Infinity (AUCinf) of Doxycycline56.297 ± 10.334854.026 ± 11.4855
Statistical analysis
  • Doxycycline Monohydrate vs Doxycycline Carragenate · Ratio: 104.67 · 90% CI 98.95 to 110.73The adjusted mean differences and 90% CIs were exponentiated to provide the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios. Doxycycline carragenate=Reference, doxycycline monohydrate=Test.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Doxycycline Monohydrate—0/24 (0%)1/24 (4.2%)
Doxycycline Carragenate—0/24 (0%)2/24 (8.3%)
Most frequent other events
Most frequent other events
EventDoxycycline MonohydrateDoxycycline Carragenate
LeukopeniaBlood and lymphatic system disorders0/241/24
ExcoriationInjury, poisoning and procedural complications0/241/24
UrticariaSkin and subcutaneous tissue disorders1/240/24

Baseline characteristics

Age, Customized
Age, Customized(participants)Entire Study Population
< 18 years0
18 to 44 years24
45 to 64 years0
> = 65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female0
Male24
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Entire Study Population
Asian24
08

Study locations

1 site
  • Pfizer Investigational Site
    Ahmedabad, Gujarat 380 015, India
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2009
First posted
Jul 15, 2009
Start
Nov 2008
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Dec 23, 2009
Last update
Dec 23, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00939562
Lead sponsor
Pfizer
First posted
Jul 15, 2009
Start date
Nov 2008
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Dec 23, 2009
Last update
Dec 23, 2009

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxycycline

Start the discussion